Y-mAbs Therapeutics Financial Statements 2016-2025 | YMAB

Revenue

$87.685

$84.819

$65.267

$34.897

$20.75

Cost Of Goods Sold

$15.001

$11.366

$7.467

$2.304

Gross Profit

$72.684

$73.453

$57.8

$32.593

$20.75

Research And Development Expenses

$48.99

$54.219

$91.572

$93.245

$93.697

$63.492

$34.269

$14.307

$13.855

SG&A Expenses

$54.645

$44.856

$60.939

$54.571

$44.785

$19.512

$8.961

$4.937

$3.184

Other Operating Income Or Expenses

$-0.25

$-0.05

$-0.1

$-0.21

$-2.203

Operating Expenses

$103.885

$99.125

$152.611

$148.026

Operating Income

$-31.201

$-25.672

$-94.811

$-115.433

$-119.935

$-83.004

$-43.23

$-19.244

$-17.039

Total Non-Operating Income/Expense

$1.389

$4.806

$-0.757

$60.158

$0.598

$1.976

$-0.044

$0.083

$-0.018

Pre-Tax Income

$-29.812

$-20.866

$-95.568

$-55.275

$-119.337

$-81.028

$-43.274

$-19.161

$-17.057

Income Taxes

$-0.146

$0.561

Income After Taxes

$-29.666

$-21.427

$-95.568

$-55.275

$-119.337

$-81.028

$-43.274

$-19.161

$-17.057

Other Income

Income From Continuous Operations

$-29.666

$-21.427

$-95.568

$-55.275

$-119.337

$-81.028

$-43.274

$-19.161

$-17.057

Income From Discontinued Operations

Net Income

$-29.666

$-21.427

$-95.568

$-55.275

$-119.337

$-81.028

$-43.274

$-19.161

$-17.057

EBITDA

$-30.666

$-24.937

$-93.972

$-114.651

$-119.539

$-82.838

$-43.201

$-19.244

$-17.039

EBIT

$-31.201

$-25.672

$-94.811

$-115.433

$-119.935

$-83.004

$-43.23

$-19.244

$-17.039

Basic Shares Outstanding

Shares Outstanding

Basic EPS

$-0.67

$-0.49

$-2.19

$-1.28

$-2.97

$-2.30

$-1.50

$-0.99

$-1.21

EPS - Earnings Per Share

$-0.67

$-0.49

$-2.19

$-1.28

$-2.97

$-2.30

$-1.50

$-0.99

$-1.21